Answers are grounded in this paper and cite their sources.
Demonstrates tumor rejection in multiple myeloma with minimized graft-versus-host disease risk, implying a safer immunotherapy approach.
targets; however, although TR cells proved highly alloreactive, SE cells showed a favorable safety profile. Accordingly, when infused in NSG mice previously engrafted with myeloma, SE cells mediated tumor rejection without inducing xenogeneic graft-versus-host disease, thus resulting in significantly higher survival than that observed in mice treated with TR cells. Overall, single TCR gene editing represents a clinically feasible approach that is able to increase the safety and efficacy of cancer adoptive immunotherapy.
No takes yet. Share an insight, caveat, or question.
Mastaglio et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: